The goal of this clinical trial is to compare the effectiveness of two promising implants in treatment of lower eyelid retraction in 40 patients. This condition often resulting from injury, surgical complications, or thyroid eye disease. The main questions it aims to answer are: Which implant provides better long-term stability of the eyelid malposition? Does one implant minimize complications and improve patient outcomes more effectively than the other? This study will compare the use of donor sclera implants to a cellular dermal matrix to see if either offers superior results in terms of reducing graft shrinkage and improving eyelid positioning. Participants will: Undergo lower eyelid reconstruction surgery with one of the two implants. Be monitored for postoperative outcomes, including eyelid position, recurrence rates, and complications over a follow-up period 6 months.
The study aims to find the best way to surgically correct lower eyelid retraction, a condition where the lower eyelid droops, leading to eye dryness, irritation, and potential vision problems. This condition can arise from various causes like thyroid eye disease, complications from eyelid or eye socket surgeries, burns, or injuries. The goal of the study is to determine which "spacer" graft works best to lift the eyelid back into its correct position and provide long-lasting results. Currently, there's no universally agreed-upon optimal spacer-graft for this condition. Surgeons at the department of Ophthalmology at Haukeland University Hospital are conducting a study to compare two promising spacer graft materials: acellular dermal matrix (Permacol), a processed tissue that encourages tissue regeneration, and autologous tarsus, tissue taken from the patient's own upper eyelid. Forty patients needing surgery for lower eyelid retraction will be inculded in this study. They will be randomly assigned to receive either the Permacol graft or the autologous tarsus graft. The surgical procedure involves making an incision inside the lower eyelid, separating the retractors (muscles that pull the eyelid down), and inserting the chosen spacer graft between the tarsus (the eyelid's supporting structure) and the retractors. This lifts the eyelid to the correct position. Patients will be followed up for six months after surgery. Doctors will measure the position of the eyelid, how well the eye closes, and signs of dryness or damage to the eye surface. Patients will also be asked about pain/discomfort, and satisfaction with the cosmetic outcome. The study will track any complications, such as infection or recurrence of the eyelid retraction. The study will compare the two groups to see which graft provides better eyelid positioning, reduces symptoms, and has fewer complications. Statistical analysis will be used to determine if there are significant differences between the two treatment groups. The results of this study will provide valuable information for surgeons treating lower eyelid retraction, helping them choose the most effective and safe graft material for their patients. The procedures will be performed by experienced surgeons at Haukeland University Hospital, ensuring patient safety. The study adheres to ethical guidelines, and patients will provide informed consent before participating.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Surgical implantation of autologous tarsus to the lower eyelid
Surgical implantation of acellular dermal matrix to the lower eyelid
Haukeland University Hospital
Bergen, Vetslandet, Norway
RECRUITINGMedial reflex distance 2
Number of patients with ≥ 1 mm reduction in medial reflex distance 2
Time frame: From baseline to 6 months follow-up.
Vertical eyelid aperture
Number of patients with ≥ 1 mm reduction in vertical eyelid aperture
Time frame: From baseline to 6 months follow-up.
Scleral show
Number of patients with ≥ 1 mm reduction in scleral show .
Time frame: From baseline to 6 months follow-up.
Lagophthalmos
Number of patients with ≥ 1 mm reduction in lagophthalmos .
Time frame: From baseline to 6 months follow-up.
Oxford staining scale
Number of patients with ≥ 1 reduction in Oxford staining scale (objective assessment of keratopathy). Oxford staining scale range from 0-4, and a higher score mean a worse outcome. .
Time frame: From baseline to 6 months follow-up.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.